141 related articles for article (PubMed ID: 18700563)
21. Candesartan reduces cardiovascular events in patients on chronic haemodialysis.
Almirall J; Valenzuela MP; Lopez T
Nephrol Dial Transplant; 2007 Jan; 22(1):281; author reply 281-2. PubMed ID: 17085461
[No Abstract] [Full Text] [Related]
22. [Significance of treating prehypertension with an angiotensin-receptor blocker--results from TROPHY study].
Umemura S
Nihon Rinsho; 2008 Mar; 66(3):601-9. PubMed ID: 18326331
[TBL] [Abstract][Full Text] [Related]
23. [Oxidative stress and mild hypertension].
Saito Y; Nakamura T; Kurabayashi M
Nihon Rinsho; 2008 Aug; 66(8):1525-9. PubMed ID: 18700552
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular protection with candesartan in patients with metabolic disorders.
Barrios V; Escobar C; Calderon A
Hypertens Res; 2010 Dec; 33(12):1312-3. PubMed ID: 20664548
[No Abstract] [Full Text] [Related]
25. Treatment options for prehypertension.
Nesbitt SD
Curr Opin Nephrol Hypertens; 2007 May; 16(3):250-5. PubMed ID: 17420669
[TBL] [Abstract][Full Text] [Related]
26. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.
Takahashi A; Takase H; Toriyama T; Sugiura T; Kurita Y; Ueda R; Dohi Y
Nephrol Dial Transplant; 2006 Sep; 21(9):2507-12. PubMed ID: 16766543
[TBL] [Abstract][Full Text] [Related]
27. [E-COST].
Kanno Y; Suzuki H
Nihon Rinsho; 2006 Aug; 64 Suppl 6():480-5. PubMed ID: 16981581
[No Abstract] [Full Text] [Related]
28. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
[TBL] [Abstract][Full Text] [Related]
30. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Candesartan versus Metoprolol for treatment of systemic hypertension after repaired aortic coarctation.
Moltzer E; Mattace Raso FU; Karamermer Y; Boersma E; Webb GD; Simoons ML; Danser AH; van den Meiracker AH; Roos-Hesselink JW
Am J Cardiol; 2010 Jan; 105(2):217-22. PubMed ID: 20102922
[TBL] [Abstract][Full Text] [Related]
32. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
33. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
[TBL] [Abstract][Full Text] [Related]
34. Carryover effects after cessation of drug treatment: trophies or dreams?
Lumley T; Rice KM; Psaty BM
Am J Hypertens; 2008 Jan; 21(1):14-6. PubMed ID: 18091738
[TBL] [Abstract][Full Text] [Related]
35. Treating prehypertension.
Lopez-Plasencia Y; Amela-Peris R; Garcia-Delgado Y
N Engl J Med; 2006 Jul; 355(4):416-7; author reply 417-8. PubMed ID: 16874902
[No Abstract] [Full Text] [Related]
36. The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients.
Jearnsujitwimol V; Eiam-Ong S; Kanjanabuch T; Wathanavaha A; Pansin P
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S188-95. PubMed ID: 17044472
[TBL] [Abstract][Full Text] [Related]
37. Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension.
Sasamura H; Kitamura Y; Nakamura M; Ryuzaki M; Saruta T
Clin Exp Hypertens; 2006 Jul; 28(5):511-20. PubMed ID: 16820347
[TBL] [Abstract][Full Text] [Related]
38. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Ogihara T; Fujimoto A; Nakao K; Saruta T;
Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
[TBL] [Abstract][Full Text] [Related]
39. An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).
Williams SA; Michelson EL; Cain VA; Yang M; Nesbitt SD; Egan BM; Julius S;
J Clin Hypertens (Greenwich); 2008 Jun; 10(6):436-42. PubMed ID: 18550933
[TBL] [Abstract][Full Text] [Related]
40. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
